FI56377C - Foerfarande foer framstaellning av 7-benzoylindolin-2-oner som foerhindrar inflammation foerorsakad av lungsaecksirritation - Google Patents
Foerfarande foer framstaellning av 7-benzoylindolin-2-oner som foerhindrar inflammation foerorsakad av lungsaecksirritation Download PDFInfo
- Publication number
- FI56377C FI56377C FI1452/73A FI145273A FI56377C FI 56377 C FI56377 C FI 56377C FI 1452/73 A FI1452/73 A FI 1452/73A FI 145273 A FI145273 A FI 145273A FI 56377 C FI56377 C FI 56377C
- Authority
- FI
- Finland
- Prior art keywords
- benzoylindolin
- formula
- inflammation
- lungsaecksirritation
- foerorsakad
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title claims description 5
- 230000004054 inflammatory process Effects 0.000 title claims description 5
- APGQYYFHBPQPTL-UHFFFAOYSA-N 7-benzoyl-1,3-dihydroindol-2-one Chemical class C=1C=CC=2CC(=O)NC=2C=1C(=O)C1=CC=CC=C1 APGQYYFHBPQPTL-UHFFFAOYSA-N 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229920002261 Corn starch Polymers 0.000 claims description 2
- 240000006394 Sorghum bicolor Species 0.000 claims description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims description 2
- 235000009430 Thespesia populnea Nutrition 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- AYUWVERWZCNJPS-UHFFFAOYSA-N 2-(2-acetamido-3-benzoylphenyl)acetic acid Chemical compound CC(=O)NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=CC=C1 AYUWVERWZCNJPS-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- SGQRIUSTBMAYKH-UHFFFAOYSA-N ethyl 2-(2-acetamido-3-benzoylphenyl)acetate Chemical compound CCOC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1NC(C)=O SGQRIUSTBMAYKH-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- MHNAXLAGKSOPBH-UHFFFAOYSA-N 1-amino-3h-indol-2-one Chemical class C1=CC=C2N(N)C(=O)CC2=C1 MHNAXLAGKSOPBH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- UVSBYFSXFHZBHB-UHFFFAOYSA-N 7-(4-chlorobenzoyl)-1,3-dihydroindol-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)C1=CC=CC2=C1NC(=O)C2 UVSBYFSXFHZBHB-UHFFFAOYSA-N 0.000 description 2
- FTKIXYMRJIBPFA-UHFFFAOYSA-N 7-benzoyl-3-methyl-1,3-dihydroindol-2-one Chemical compound CC1C(=O)NC2=C1C=CC=C2C(=O)C1=CC=CC=C1 FTKIXYMRJIBPFA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- TWGHEAQMIPDUKJ-UHFFFAOYSA-N ethyl 2-(2-methyl-3-phenyl-1h-indol-7-yl)acetate Chemical compound CC=1NC=2C(CC(=O)OCC)=CC=CC=2C=1C1=CC=CC=C1 TWGHEAQMIPDUKJ-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006385 ozonation reaction Methods 0.000 description 1
- QCCDLTOVEPVEJK-UHFFFAOYSA-N phenylacetone Chemical compound CC(=O)CC1=CC=CC=C1 QCCDLTOVEPVEJK-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- -1 α-methylphenethylideneamino Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B45/00—Complex metal compounds of azo dyes
- C09B45/02—Preparation from dyes containing in o-position a hydroxy group and in o'-position hydroxy, alkoxy, carboxyl, amino or keto groups
- C09B45/24—Disazo or polyazo compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B35/00—Disazo and polyazo dyes of the type A<-D->B prepared by diazotising and coupling
- C09B35/02—Disazo dyes
- C09B35/039—Disazo dyes characterised by the tetrazo component
- C09B35/08—Disazo dyes characterised by the tetrazo component the tetrazo component being a derivative of biphenyl
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Coloring (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25428472A | 1972-05-17 | 1972-05-17 | |
| US25428472 | 1972-05-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI56377B FI56377B (fi) | 1979-09-28 |
| FI56377C true FI56377C (fi) | 1980-01-10 |
Family
ID=22963675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI1452/73A FI56377C (fi) | 1972-05-17 | 1973-05-07 | Foerfarande foer framstaellning av 7-benzoylindolin-2-oner som foerhindrar inflammation foerorsakad av lungsaecksirritation |
Country Status (17)
| Country | Link |
|---|---|
| JP (2) | JPS5139222B2 (en, 2012) |
| AT (1) | AT323731B (en, 2012) |
| BE (2) | BE799612A (en, 2012) |
| CA (1) | CA1000715A (en, 2012) |
| CH (1) | CH577469A5 (en, 2012) |
| DE (2) | DE943075C (en, 2012) |
| DK (1) | DK139677B (en, 2012) |
| ES (1) | ES414802A1 (en, 2012) |
| FI (1) | FI56377C (en, 2012) |
| FR (1) | FR2184933B1 (en, 2012) |
| GB (1) | GB1432577A (en, 2012) |
| IE (1) | IE37641B1 (en, 2012) |
| IL (1) | IL42216A (en, 2012) |
| NL (2) | NL183187C (en, 2012) |
| PH (1) | PH9815A (en, 2012) |
| SE (1) | SE393980B (en, 2012) |
| ZA (1) | ZA733151B (en, 2012) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5371842U (en, 2012) * | 1976-11-17 | 1978-06-15 | ||
| US4221716A (en) * | 1979-02-16 | 1980-09-09 | A. H. Robins Company, Inc. | Intermediate and process for the preparation of 7-acylindolin-2-ones |
| DE3300522A1 (de) * | 1982-01-21 | 1983-07-28 | Sandoz-Patent-GmbH, 7850 Lörrach | 3,3-dialkyl- und 3,3-alkylen-indolinderivate, verfahren zu ihrer herstellung und pharmazeutische praeparate sie enthaltend |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH232507A (de) * | 1941-02-18 | 1944-05-31 | Chem Ind Basel | Verfahren zur Herstellung eines Disazofarbstoffes. |
-
0
- BE BE524637D patent/BE524637A/xx unknown
- NL NL90149D patent/NL90149C/xx active
-
1953
- 1953-11-25 DE DEC8502A patent/DE943075C/de not_active Expired
-
1973
- 1973-05-07 FI FI1452/73A patent/FI56377C/fi active
- 1973-05-08 IL IL42216A patent/IL42216A/en unknown
- 1973-05-09 ZA ZA733151A patent/ZA733151B/xx unknown
- 1973-05-11 DK DK263073AA patent/DK139677B/da unknown
- 1973-05-11 PH PH14608A patent/PH9815A/en unknown
- 1973-05-15 CH CH689973A patent/CH577469A5/xx not_active IP Right Cessation
- 1973-05-15 SE SE7306853A patent/SE393980B/xx unknown
- 1973-05-16 BE BE131181A patent/BE799612A/xx not_active IP Right Cessation
- 1973-05-16 ES ES414802A patent/ES414802A1/es not_active Expired
- 1973-05-16 FR FR7317755A patent/FR2184933B1/fr not_active Expired
- 1973-05-16 AT AT429973A patent/AT323731B/de not_active IP Right Cessation
- 1973-05-16 DE DE2324767A patent/DE2324767C2/de not_active Expired
- 1973-05-16 GB GB2337473A patent/GB1432577A/en not_active Expired
- 1973-05-16 CA CA171,512A patent/CA1000715A/en not_active Expired
- 1973-05-16 NL NLAANVRAGE7306832,A patent/NL183187C/xx not_active IP Right Cessation
- 1973-05-17 IE IE785/73A patent/IE37641B1/xx unknown
- 1973-05-17 JP JP48054204A patent/JPS5139222B2/ja not_active Expired
-
1976
- 1976-05-13 JP JP51054786A patent/JPS5910660B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| PH9815A (en) | 1976-03-26 |
| DE2324767C2 (de) | 1985-07-25 |
| IE37641L (en) | 1973-11-17 |
| NL90149C (en, 2012) | |
| JPS4941366A (en, 2012) | 1974-04-18 |
| DK139677C (en, 2012) | 1979-09-10 |
| NL183187B (nl) | 1988-03-16 |
| SE393980B (sv) | 1977-05-31 |
| FR2184933A1 (en, 2012) | 1973-12-28 |
| FI56377B (fi) | 1979-09-28 |
| NL183187C (nl) | 1988-08-16 |
| IL42216A (en) | 1976-08-31 |
| AU5584773A (en) | 1974-11-21 |
| CA1000715A (en) | 1976-11-30 |
| DE943075C (de) | 1956-05-09 |
| AT323731B (de) | 1975-07-25 |
| IE37641B1 (en) | 1977-09-14 |
| CH577469A5 (en, 2012) | 1976-07-15 |
| FR2184933B1 (en, 2012) | 1976-05-14 |
| ZA733151B (en) | 1974-04-24 |
| NL7306832A (en, 2012) | 1973-11-20 |
| DE2324767A1 (de) | 1973-11-29 |
| GB1432577A (en) | 1976-04-22 |
| IL42216A0 (en) | 1973-07-30 |
| JPS5910660B2 (ja) | 1984-03-10 |
| BE524637A (en, 2012) | |
| JPS5217466A (en) | 1977-02-09 |
| DK139677B (da) | 1979-03-26 |
| ES414802A1 (es) | 1976-02-01 |
| JPS5139222B2 (en, 2012) | 1976-10-26 |
| BE799612A (fr) | 1973-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1087205A (en) | 2-amino-3-(5-and 6-)benzoylphenylacetic acids, esters and metal salts thereof | |
| US3770752A (en) | Process for producing n1-acylated phenylhydrazone compounds | |
| EP0516588B1 (de) | Substituierte Diaminophthalimide und Analoga | |
| RU1796625C (ru) | 3-Амино-7-нитро-4(2,3,4-триметоксифенил)-2-фенил-1(2Н)изохинолон, обладающий аналептическим действием | |
| Sternbach et al. | Quinazolines and 1, 4-Benzodiazepines. XI. 1 Synthesis and Transformations of 7-Chloro-2, 3-dihydro (and 2, 3, 4, 5-tetrahydro)-5-phenyl-1H-1, 4-benzodiazepine2 | |
| NZ197582A (en) | Dextrorotatory trans-4a,9b-5phenyl-2,3,4,4a,5,9b-hexahydro-1h-pyrido(4,3-b) indoles | |
| US4755619A (en) | Pharmaceutical compositions | |
| RU2036929C1 (ru) | Эфиры эстрамастина или их фармацевтически приемлемые соли и способ их получения | |
| FI56377C (fi) | Foerfarande foer framstaellning av 7-benzoylindolin-2-oner som foerhindrar inflammation foerorsakad av lungsaecksirritation | |
| DE3030462A1 (de) | Polyprenylcarbonsaeureamide, verfahren zu deren herstellung sowie diese verbindung enthaltende arzneimittel | |
| JPS6239564A (ja) | α−ベンジリデン−γ−ブチロラクトンまたはγ−ブチロラクタム誘導体 | |
| IL33846A (en) | Derivatives of 1-thiachromone and 4-thionchromone,their preparation and pharmaceutical compositions containing them | |
| HU199683B (en) | Process for producing pharmaceutical compositions analgesic, antiphlogistic, antipyretic, antianginic and/or antioxidative activity | |
| US3030371A (en) | Process for the preparation of d-and l-aryl-(2-pyridyl)-amino alkanes | |
| EP0065295A1 (de) | Substituierte Tryptaminderivate von Thienyloxypropanolaminen, Verfahren zu ihrer Herstellung, pharmazeutische Präparate auf Basis dieser Verbindungen sowie ihre Verwendung | |
| FR2522000A1 (fr) | Nouvelles thiopyrannopyrimidines, utiles notamment comme agents hypoglycemiants, et leur fabrication | |
| US3926988A (en) | Substituted pyrazoles | |
| US3711609A (en) | Certain furazan derivatives in therapeutic compositions and methods | |
| US3666803A (en) | N-hydroxyalkyl-2,4,6-triiodosuccinanilic acids | |
| US3900563A (en) | Method of using 3-(2-(4-phenyl-1-piperazinyl)ethyl)-indolines | |
| US20050043396A1 (en) | 5-Benzoylamino-1,3-dioxacyclanes, the method for preparing the same and their use as PKC inhibitor | |
| US3941806A (en) | 7-(α-Acetylbenzyl)indoline | |
| US5149710A (en) | Pharmaceutical compositions for treating psoriasis | |
| US5162372A (en) | Pharmaceutical compositions for treating certain cancers | |
| EP0336068A1 (en) | Phenoxyalkoxy-3,4-dihydro-2H-1-benzopyran derivatives |